SHIRE ORD 5P overview

Shire and SAIIDAC announce planned delisting of notes from the New York Stock Exchange Dublin, Ireland – January 11, 2019 – Shire plc (“Shire”) and Shire Acquisitions Investments Ireland DAC, an Irish designated activity company and wholly-owned subsidiary of Shire (“SAIIDAC”), announced today that they have notified the New York Stock Exchange (the “NYSE”) of their intention to apply for the voluntary delisting of SAIIDAC’s outstanding 1.900% Senior Notes due 2019, 2.400%...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE JANUARY 9, 2019 RECOMMENDED OFFER for SHIRE PLC by TAKEDA PHARMACEUTICAL COMPANY LIMITED De-listing and cancellation of trading of Shire Shares Further to the announcement made by Shire plc (“ Shire ”) on January 8, 2019, Shire today announces that, following an...

Director/PDMR Shareholding January 8, 2019 – Shire plc (LSE: SHP, NASDAQ: SHPG) (the “Company”) Notification of transactions by persons discharging managerial responsibilities 1. Details of the person discharging managerial responsibilities (“PDMR”) / person closely associated with them (“PCA”) a) Name Flemming Ornskov 2. Reason for the notification a) Position / status Chief Executive Officer - PDMR b) Initial notification / amendment Initial notification 3. Details of the issuer,...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE JANUARY 8, 2019 RECOMMENDED OFFER for SHIRE PLC by TAKEDA PHARMACEUTICAL COMPANY LIMITED Scheme becomes effective On May 8, 2018, Shire plc (“ Shire ”) and Takeda Pharmaceutical Company Limited (“ Takeda ”) announced that they had reached agreement on the...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE JANUARY 8, 2019 RECOMMENDED OFFER for SHIRE PLC by TAKEDA PHARMACEUTICAL COMPANY LIMITED Scheme becomes effective On May 8, 2018, Shire plc (“ Shire ”) and Takeda Pharmaceutical Company Limited (“ Takeda ”) announced that they had reached agreement on the...

Holding(s) in Company January 7, 2019 – Shire plc (LSE: SHP, NASDAQ: SHPG) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Shire Plc JE00B2QKY057 1b. Please indicate if the issuer is a non-UK issuer (please mark with an “X” if appropriate) Non-UK issuer X 2. Reason for the notification (please mark the appropriate box or boxes with an “X”) An acquisition or disposal of voting rights An acquisition or disposal of financial...

HBK Investments LP - Form 8.3 - Shire Plc PR Newswire London, January 7 FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: HBK Investments L.P. on behalf of itself, its subadvisors and its managed funds (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION FOR IMMEDIATE RELEASE JANUARY 3, 2019 RECOMMENDED OFFER for SHIRE PLC by TAKEDA PHARMACEUTICAL COMPANY LIMITED Court sanction of the Scheme Shire plc (“ Shire ”) is pleased to announce that the Royal Court of Jersey has today sanctioned the scheme of arrangement pursuant to Article...